Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
暂无分享,去创建一个
C. Di Serio | L. Naldini | M. Roncarolo | F. Mavilio | A. Aiuti | A. Ambrosi | Giulietta Maruggi | V. Hernandez-Trujillo | B. Cassani | M. Mirolo | E. Montini | S. Selleri | E. Biral | I. Frugnoli | Erika Biral | Ilaria Frugnoli
[1] Alessandro Aiuti,et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.
[2] L. Notarangelo,et al. How I treat ADA deficiency. , 2009, Blood.
[3] Christof von Kalle,et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.
[4] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[5] Christine Kinnon,et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.
[6] A. Schambach,et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16 , 2008, Leukemia.
[7] JM Kim,et al. Toxicity of repeated intravenous injection of gene therapeutics for X-CGD in mice , 2008, Human & experimental toxicology.
[8] M. Roncarolo,et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. , 2008, Blood.
[9] A. Schambach,et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] Alessandro Aiuti,et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. , 2007, Blood.
[11] Christine Kinnon,et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.
[12] Bruce Aronow,et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.
[13] Luca Biasco,et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.
[14] M. Grez,et al. Advances in the treatment of Chronic Granulomatous Disease by gene therapy. , 2007, Current gene therapy.
[15] C. Di Serio,et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. , 2006, Blood.
[16] Kathryn L. Parsley,et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] M. Reinders,et al. Gene therapy: Is IL2RG oncogenic in T-cell development? , 2006, Nature.
[18] A. Schambach,et al. Gene therapy: X-SCID transgene leukaemogenicity , 2006, Nature.
[19] T. Lu,et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[20] Christine Kinnon,et al. Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.
[21] A. Nienhuis,et al. Genotoxicity of retroviral integration in hematopoietic cells. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] I. Verma,et al. Gene therapy: Therapeutic gene causing lymphoma , 2006, Nature.
[23] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[24] C. Bordignon,et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[25] P. Good. Permutation, Parametric, and Bootstrap Tests of Hypotheses , 2005 .
[26] C. von Kalle,et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. , 2005, Blood.
[27] B. Fehse,et al. Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.
[28] E. Medico,et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. , 2005, Blood.
[29] Christof von Kalle,et al. Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells , 2004, PLoS biology.
[30] Alessandro Aiuti,et al. Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. , 2003, Clinical chemistry.
[31] Shawn M. Burgess,et al. Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.
[32] C. Dunbar,et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. , 2003, Blood.
[33] A. Mortellaro,et al. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.
[34] A. West,et al. Insulators: many functions, many mechanisms. , 2002, Genes & development.
[35] F. Deist,et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.
[36] K. Sullivan,et al. Adenosine Deaminase Deficiency and Purine Nucleoside Phosphorylase Deficiency in Common Variable Immunodeficiency , 1998, Clinical Diagnostic Laboratory Immunology.
[37] C. Bordignon,et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.
[38] G. Mann,et al. Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts. , 1986, The Journal of clinical investigation.
[39] E. Gelfand,et al. Increased Excretion of Modified Adenine Nucleosides by Children with Adenosine Deaminase Deficiency , 1982, Pediatric Research.
[40] M. Hershfield,et al. In vivo inactivation of erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase-deficient patients. , 1979, The Journal of clinical investigation.
[41] H. Simmonds,et al. A ROLE FOR PURINE METABOLISM IN THE IMMUNE RESPONSE: ADENOSINE-DEAMINASE ACTIVITY AND DEOXYADENOSINE CATABOLISM , 1978, The Lancet.
[42] H. Green,et al. Pyrimidine Starvation Induced by Adenosine in Fibroblasts and Lymphoid Cells: Role of Adenosine Deaminase , 1973, Science.
[43] Valérie Ventura,et al. Bootstrap Tests of Hypotheses , 2010 .
[44] A. Marusyk,et al. Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations. , 2008, Biochimica et biophysica acta.
[45] D. Kohn. Gene therapy for childhood immunological diseases , 2008, Bone Marrow Transplantation.
[46] E. Ziegel. Permutation, Parametric, and Bootstrap Tests of Hypotheses (3rd ed.) , 2005 .
[47] P. Good. Permutation, Parametric, and Bootstrap Tests of Hypotheses (Springer Series in Statistics) , 1994 .
[48] D. Perrett,et al. Purine metabolism in adenosine deaminase deficiency. , 1978, Ciba Foundation symposium.